KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Teva Pharmaceutical Industries (TEVA) Receivables - Net (2016 - 2025)

Teva Pharmaceutical Industries' Receivables - Net history spans 17 years, with the latest figure at $3.7 billion for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 21.25% year-over-year to $3.7 billion, compared with a TTM value of $3.7 billion through Dec 2025, up 21.25%, and an annual FY2025 reading of $3.7 billion, up 21.25% over the prior year.
  • Receivables - Net for Q4 2025 was $3.7 billion at Teva Pharmaceutical Industries, down from $3.8 billion in the prior quarter.
  • The five-year high for Receivables - Net was $4.6 billion in Q1 2021, with the low at $3.1 billion in Q4 2024.
  • Average Receivables - Net over 5 years is $3.8 billion, with a median of $3.7 billion recorded in 2022.
  • Year-over-year, Receivables - Net dropped 20.85% in 2023 and then increased 21.25% in 2025.
  • Tracing TEVA's Receivables - Net over 5 years: stood at $4.5 billion in 2021, then dropped by 18.39% to $3.7 billion in 2022, then fell by 7.79% to $3.4 billion in 2023, then decreased by 10.24% to $3.1 billion in 2024, then rose by 21.25% to $3.7 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Receivables - Net are $3.7 billion (Q4 2025), $3.8 billion (Q3 2025), and $3.6 billion (Q2 2025).